Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 4:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 9,118 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Recurrent Neoplasm Clear all
Completed Phase 1Phase 2 Interventional Results available

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

NCT03008278
View directory record Official record
Conditions
Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Unresectable Esophageal Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Interventions
Olaparib, Ramucirumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
32
States / cities
Corona, California • Duarte, California • Lancaster, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 31, 2026, 4:14 AM EDT
Completed Phase 1 Interventional

Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00040950
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, agatolimod sodium
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 31, 2026, 4:14 AM EDT
Recruiting Phase 1 Interventional

Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252

NCT06126744
View directory record Official record
Conditions
Recurrent High Grade Glioma
Interventions
MVR-C5252
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 31, 2026, 4:14 AM EDT
Completed Phase 2 Interventional

Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00138164
View directory record Official record
Conditions
Lymphoma
Interventions
denileukin diftitox
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 31, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer

NCT03196232
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Unresectable Esophageal Carcinoma
Interventions
Epacadostat, Pembrolizumab
Drug
Lead sponsor
George Albert Fisher
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 31, 2026, 4:14 AM EDT
Completed Phase 1 Interventional

Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers

NCT03017833
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Refractory Neoplasm
Interventions
Laboratory Biomarker Analysis, Metformin, Pharmacological Study, Sapanisertib
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 31, 2026, 4:14 AM EDT
Completed Phase 3 Interventional

Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

NCT00002855
View directory record Official record
Conditions
Prostate Cancer
Interventions
Bicalutamide, Doxorubicin hydrochloride, Estramustine Phosphate Sodium, Flutamide, Ketoconazole, Nilutamide, Therapeutic Hydrocortisone, Vinblastine, Conventional Surgery
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 31, 2026, 4:14 AM EDT
Withdrawn Phase 2 Interventional

Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.

NCT00874315
View directory record Official record
Conditions
Neuroblastoma
Interventions
anti-thymocyte globulin, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic hematopoietic stem cell transplantation
Other · Drug · Procedure
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Year to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2015 · Synced Oct 31, 2026, 4:14 AM EDT
Terminated Phase 2 Interventional

Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma

NCT00019864
View directory record Official record
Conditions
Cardiac Toxicity, Sarcoma
Interventions
filgrastim, cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride, leucovorin calcium, methotrexate, adjuvant therapy, conventional surgery, neoadjuvant therapy
Biological · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
4
States / cities
Bethesda, Maryland • Oklahoma City, Oklahoma • Fort Worth, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 31, 2026, 4:14 AM EDT
Recruiting Early Phase 1 Interventional

An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial

NCT06813898
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Computed Tomography, Electronic Health Record Review, Flotufolastat F-18 Gallium, Positron Emission Tomography
Procedure · Other · Drug
Lead sponsor
Northwestern University
Other
Eligibility
Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 31, 2026, 4:14 AM EDT
Completed Phase 2 Interventional

Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma

NCT00004033
View directory record Official record
Conditions
Malignant Mesothelioma
Interventions
liposomal NDDP, therapeutic thoracoscopy
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Oct 31, 2026, 4:14 AM EDT
Completed No phase listed Observational

S9007, Study of Bone Marrow and Blood Samples From Patients With Leukemia or Other Hematopoietic Cancers

NCT00996047
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
cytogenetic analysis, fluorescence in situ hybridization
Genetic
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
3,341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2012
U.S. locations
280
States / cities
Mobile, Alabama • Anchorage, Alaska • Tucson, Arizona + 182 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 31, 2026, 4:14 AM EDT
Completed Phase 1 Interventional

Paclitaxel Plus Chemoprotection With Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors

NCT00003555
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
amifostine trihydrate, paclitaxel
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 31, 2026, 4:14 AM EDT
Completed Phase 4 Interventional Results available

Postoperative Effects of Intranasal Fentanyl, IV and IM Morphine in Children Undergoing Myringotomy

NCT01244126
View directory record Official record
Conditions
Otitis Media
Interventions
Intranasal fentanyl, morphine IM, IV morphine
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
6 Months to 6 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 31, 2026, 4:14 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

NCT07464925
View directory record Official record
Conditions
Glioblastoma Multiforme of Brain, Glioma, Glioblastoma
Interventions
GLIX1
Drug
Lead sponsor
Tetragon Biosciences Ltd
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Tampa, Florida • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 31, 2026, 4:14 AM EDT
Withdrawn Phase 2 Interventional

Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant

NCT03328936
View directory record Official record
Conditions
Hematopoietic Cell Transplantation Recipient, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Laboratory Biomarker Analysis, Melphalan Hydrochloride, Pharmacological Study
Other · Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 31, 2026, 4:14 AM EDT
Completed Phase 1Phase 2 Interventional

Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction

NCT00004911
View directory record Official record
Conditions
Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor, Quality of Life, Small Intestine Cancer
Interventions
bowel obstruction management, quality-of-life assessment
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 31, 2026, 4:14 AM EDT
Completed No phase listed Observational

Self-Care for Lymphedema in Patients With Breast Cancer

NCT00670644
View directory record Official record
Conditions
Breast Cancer
Interventions
questionnaire administration, survey administration, quality-of-life assessment
Other · Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 31, 2026, 4:14 AM EDT
Completed Phase 2 Interventional

Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma

NCT00004192
View directory record Official record
Conditions
Lymphoma, Neutropenia
Interventions
filgrastim, pegfilgrastim, cisplatin, cytarabine, etoposide, methylprednisolone
Biological · Drug
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
3
States / cities
Los Angeles, California • Omaha, Nebraska • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 31, 2026, 4:14 AM EDT
Terminated Phase 1 Interventional

Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies

NCT01553071
View directory record Official record
Conditions
Solid Tumor
Interventions
Fenretinide (4-HPR) plus Intravenous Safingol
Drug
Lead sponsor
South Plains Oncology Consortium
Network
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Dallas, Texas • Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 31, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

Ultrasound-Guided Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer Previously Treated With External-Beam Radiation Therapy

NCT00450411
View directory record Official record
Conditions
Prostate Cancer
Interventions
125-Iodine, 103-palladium
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
13
States / cities
Phoenix, Arizona • Fresno, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 31, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

NCT01570036
View directory record Official record
Conditions
Breast Cancer
Interventions
Herceptin, NeuVax vaccine, GM-CSF
Drug
Lead sponsor
George E. Peoples
Industry
Eligibility
18 Years and older · Female only
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
29
States / cities
Beverly Hills, California • Santa Monica, California • Santa Rosa, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 31, 2026, 4:14 AM EDT
Completed Phase 2 Interventional Results available

Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant

NCT01431209
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Interventions
Laboratory Biomarker Analysis, Ruxolitinib Phosphate
Other · Drug
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
3
States / cities
Bethesda, Maryland • Rochester, Minnesota • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 31, 2026, 4:14 AM EDT
Completed Not applicable Interventional

POLARx Post Approval Study (POLARx PAS)

NCT06170606
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation
Interventions
Boston Scientific Cardiac Cryoablation System
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 31, 2026, 4:14 AM EDT